SynthesisBMC infectious diseases2025
Global mapping of sexually transmitted Chlamydia trachomatis disease: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Worldwide prevalence ofNew microbes and new infections · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChlamydia trachomatis (C. trachomatis) is known as a leading cause of one of the most prominent sexually transmitted diseases (STD) worldwide. A meta-analysis was performed in this study to comprehensively determine the prevalence of C. trachomatis in the STD population.
methodPubMed/Medline, Embase, and Web of Science databases were used to conduct an extensive literature search on relevant papers published from 2000 to 2023. After that, statistical analysis was performed utilizing comprehensive meta-analysis (CMA) software (version 2.0, Biostat, USA) to report the global prevalence of C. trachomatis in the STD population.
resultIn prevalence studies involving an overall number of 40,159 STD individuals, 17,289 C. trachomatis isolates were collected in 86 countries worldwide, either by culture or by indirect DNA testing. The pooled prevalence of C. trachomatis within the global STD population was 41.6% (95% CI,40.1–43%), while a higher rate was recorded for males (12807 vs. 18871). The prevalence of C. trachomatis infection was highest in Oceania, followed by Europe, America, Asia, and Africa (49.9%, 46.3%, 41.3%, 41.1%, and 36.1%, respectively). According to data from case reports and case series, lymphogranuloma venereum (LGV) and human immunodeficiency virus (HIV) infection were the most common concurrent diseases and co-infections.
conclusionThe elevated prevalence of C. trachomatis in 86 countries suggests that innovative screening and infection-prevention programs are required to reduce the burden of this clinically very significant bacterial infection. Our results support the demand for further fundamental investigations in this area especially among HIV-positive patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.